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Summary 
The amyloid deposits of Alzheimer's disease contain, 
in addition to the p protein (Ap), lesser amounts of other 
proteins including the protease inhibitor m-antichy - 
motrypsin (ACT). We have recently shown that ACT 
acts as a pathological chaperone, binding to the I~ pro- 
tein and strongly promoting its polymerization into am- 
yloid filaments in vitro. The data of this paper show 
that ACT synthesis is induced in cultured human 
astrocytes by IL-1, a lymphokine whose expression 
is strongly up-regulated in microglial cells in affected 
areas of AIzheimer's disease brain. Furthermore, un- 
fractionated glial Cultures containing both astrocytes 
and microglia from human cortex (which develops am- 
yloid in Alzheimer's disease) spontaneously express 
IL-1 and ACT as they reach confluence. In contrast, 
confluent mixed glial cultures similarly prepared from 
human cerebellum or brain stem, or from rat brain-  
tissues not prone to amyloid formation-do not ex- 
press ACT unless supplemented with exogenous IL-1. 
The same regional difference in IL-1 expression by mi. 
croglia is seen in vivo in Alzheimer's disease. These 
results indicate that the IL-l-induced expression of 
ACT may help direct the region-specific production of 
mature amyloid filaments in the Alzheimer brain. 
Introduction 
The earliest detectable lesions in the brains of Alzheimer's 
disease patients (and Down syndrome patients, all of 
whom also show Alzheimer neuropathology by age 30- 
40) are amorphous, pre-amyloid eposits of 13 protein (Wis- 
niewski and Terry, 1973; Mann et al., 1985; Probst et al., 
1987; Giaccone et al., 1989; Ikeda et al., 1989). The Alzhei- 
mer 13 protein (Aj3) is an approximately 40 amino acid pep- 
tide that is derived by proteolytic processing from a larger 
amyloid precursor protein, I~APP (Glenner and Wong, 
1984; Masters et al., 1985; Goldgaber et al., 1987; Kang 
et al., 1987; Robakis et al., 1987; Tanzi et al., 1987). As 
the disease progresses, the mature Alzheimer amyloid 
arises, forming the cores of the neuritic plaques found 
predominantly in higher centers of the brain and accumu- 
lating in the walls of the cerebral and meningeal vascula- 
ture (Glenner, 1980; Selkoe, 1991). Using electron micros- 
copy, Alzheimer amyloid deposits can be seen to consist 
of large meshworks of protein filaments approximately 7
nm wide (Merz et al., 1983). The amyloid maturation pro- 
cess in Alzheimer's disease and Down syndrome presum- 
ably reflects either a conversion from the amorphous to the 
filamentous form of deposit or an independent assembly of 
the amyloid filaments. 
There are several puzzling features of the filamentous 
amyloid deposits of Alzheimer's disease and Down syn- 
drome brains. First, their deposition shows a striking re- 
gional specificity. Amorphous, pre-amyloid deposits of AJ3 
can be found in many brain regions, including the neocor- 
tex, hippocampus, and amygdala, as well as the cerebel- 
lum and brain stem (Yamaguchi et al., 1988; Joachim et 
al., 1989a). However, the mature, filamentous deposits 
arise only in certain areas, such as the neocortex, hippo- 
campus, and amygdala, and in the walls of cerebral and 
meningeal blood vessels. The second unusual feature of 
Alzheimer amyloid is the presence of other structural com- 
ponents besides the AI3 peptide. For instance, the prote- 
ase inhibitor ~l-antichymotrypsin (ACT) is intimately asso- 
ciated with the AI3 protein filaments in the mature amyloid 
of Alzheimer's disease, but is not present in the amyloid 
deposits of other diseases (Abraham et al., 1988, 1990). 
Interestingly, the amorphous AI3 deposits in nonaffected 
areas of Alzheimer brain such as the cerebellum are 
largely devoid of ACT(Abraham et al., 1988; Rozemuller et 
al., 1990, 1991), although some ACT staining of cerebellar 
plaques has been found by Shoji et al. (1991). Other com- 
ponents of Alzheimer and other amyloid include apolipo- 
protein E (apoE), heparan sulfate proteoglycan (HSPG), 
and several complement proteins (Eikelenboom, 1989; 
Snow et al., 1989; Namba et al., 1991; Wisniewski and 
Frangione, 1992). 
The presence of some associated proteins in Alzheimer 
amyloid may be due to adventitious adhesion. However, 
the strong, specific affinity of ACT, apoE, and HSPG for 
the A~ peptide in vivo and in vitro suggests that these 
proteins might participate directly in amyloid deposition 
by serving as pathological chaperones for the AI3 peptide 
(Abraham et al., 1988; Potter et al., 1991; Snow et al., 
1988, 1989, 1994; Wisniewski and Frangione, 1992; Stritt- 
matter et al., 1993; Wisniewski et al., 1993). Furthermore, 
the areas of Alzheimer brain in which mature amyloid de- 
posits accumulate are distinguished by greatly enhanced 
levels of ACT mRNA and soluble protein (Abraham et al., 
1988, 1989, 1990). We recently examined the influence 
of ACT and another putative pathological chaperone, 
apoE, on the spontaneous polymerization of AI3 into amy- 
Ioid filaments in vitro and found that these proteins strongly 
promoted filament formation (Ma et al., 1994; see also 
Wisniewski et al., 1994; Sanan et al., 199,$). Together, 
these results suggest that amyloid formation in Alzhei- 
mer's disease brain may reflect the availability not only of 
the AI3 peptide itself but of amyloid-promoting factors such 
as ACT, apoE, or HSPG. Thus, the expression of these 
proteins in the brain may be a critical step in the develop- 
ment of mature Alzheimer neuropathology. IIn this paper, 
we investigate the mechanism by which ACT, the patho- 
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logical chaperone most specific for Alzheimer amyloid, is 
overexpressed in affected areas of the Alzheimer brain. 
Unlike the AI~ protein, which is believed to be produced 
primarily by endogenous brain neurons (Card et al., 1988; 
Higgins et al., 1988; Palmert et al., 1988; Benowitz et al., 
1989; but see also Joachim et al., 1989b), ACT is derived 
from gila. In situ hybridization with ACT cRNA probes, 
coupled with ACT and glial fibrillary acidic protein (GFAP) 
immunostaining, demonstrate that the increased ACT ex- 
pression in Alzheimer brain occurs in astrocytes sur- 
rounding the amyloid deposits (Pasternack et al., 1989; 
Abraham et al., 1990; Koo et al., 1991). The increased 
immunostaining of these cells for GFAP further indicates 
that the ACT-expressing astrocytes have become reactive 
in response to a local inflammatory insult and associated 
signaling molecule(s). 
A hint as to how expression of ACT might be induced 
in astrocytes comes from the fact that, normally, this prote- 
ase inhibitor is produced in the liver as part of the body's 
response to inflammation. Specifically, certain lympho- 
kines, in particular interleukin-1 (IL-1), can induce ACT 
expression in hepatocytes both in vivo and in vitro (Bau- 
mann et al., 1987). We therefore investigated the ability 
of glial cells from different areas of human brain to express 
ACT in response to IL-1. The results of these and other 
experiments uggest that a region-specific, acute phase- 
like response in the brain, very similar to that seen in the 
liver, is a necessary link in the chain of events that leads 
first to the formation of mature amyloid deposits and ulti- 
mately to neuronal cell death and dementia. 
Results 
Experiments in vitro (Bauman net al., 1987) have indicated 
that the lymphokines IL-1 and IL-6 and the glucocorticoid 
dexamethasone are among the signal molecules that in- 
duce hepatocytes in the liver to begin overexpressing ACT 
during the peripheral acute phase response. It is perhaps 
significant hat these acute phase-inducing agents are 
present in higher amounts in the brains of Alzheimer's 
disease patients compared with age-matched control indi- 
viduals. IL-1 immunoreactivity is present in 6-fold as many 
cortical microglial cells in Alzheimer's disease patients 
compared with controls (Griffin et al., 1989; see also Caca- 
belos et al., 1994; Sheng et al., 1994), and IL-1 appears 
to cause the astrogliosis that follows brain injury (Giulian 
and Lachman, 1985). In addition, there is an increase in 
plasma cortisol and in corticotropin-releasing factor in ce- 
rebral spinal fluid in Alzheimer's disease patients (Davis 
et al., 1986; Martignoni et al., 1990). We therefore tested 
directly the ability of these agents to induce expression 
of the acute phase protein ACT in human astrocytes grown 
in vitro. 
Establishment of Primary Glial Cultures 
from Human and Rat Brain 
As described in Experimental Procedures, brain tissue 
was disaggregated, and the cells were placed in primary 
culture. After 1-2 weeks, the majority of neurons had died 
and detached from the substrate, leaving a confluent 
monolayer of glial cells. The morphology of the cells indi- 
D 
Figure 1. Immunocytochemistry of Human 
Mixed Glial Cells in Primary Culture 
Cultures were prepared as described in Experi- 
mental Procedures and grown to confluence 
in fetal calf serum-containing DMEM medium. 
Immunolabeling with a monoclonal ntibody 
against GFAP (A) demonstrates that 85%- 
90% of the cells stain for this astrocyte-specific 
protein, while the control (B), using normal goat 
serum in place of the primary antibody, shows 
only a low background staining. Immunola- 
beling with anti-ACT serum (C) indicates that 
most astrocytes grown to confluence in serum- 
containing medium express this acute phase 
protein. In (D), the primary anti-ACT serum was 
replaced with normal serum as a control. 
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cated that most were astrocytes, together with a few mi- 
croglia. This conclusion was confirmed by immunolabeling 
the cells with an antibody to the astrocyte-specific protein 
GFAP, which identified 85%-90% of the cells as astrocytes 
(Figure 1). 
Although ACT is overexpressed in astrocytes in areas 
of Alzheimer's disease brain exhibiting pathology (Abra- 
ham et al., 1988), the level of ACT mRNA and protein in 
normal age-matched control brain is undetectable (Abra- 
ham et al., 1988; see also Esiri and Booss, 1984; Justice 
et al., 1987). Following their emoval from the animal and 
initial culturing in serum-containing medium, however, 
astrocytes begin to express a high level of ACT mRNA 
and protein (Figure 1). The normal, low level of ACT ex- 
pression is reestablished by exposing the cells to serum- 
free medium for 2 hr. 
IL-1 Induces ACT Expression in Cultured 
Human Astrocytes 
As discussed above, IL-1, together with glucocorticoids, 
has been shown to be an effective inducer of ACT expres- 
sion in hepatocytes, and the level of these agents has 
been found to be elevated in AIzheimer's disease brain. 
We therefore tested the ability of I!_-1 and the glucocorti- 
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Figure 2. Induction of ACT mRNA in Human Mixed Glial Cultures 
by IL-1 
(A) Mixed glial cultures from human fetal frontal cortex were prepared 
as described in Experimental Procedures, grown to subconfluence in 
serum-containing medium, then switched to serum-free N2 medium 
for 2 hr. The cultures were then treated with IL-le (250 U/ml) and/or 
dexamethasone (1 #M) for 4 hr, at which time RNA was isolated and 
subjected to Northern blot analysis with an ACT probe. IL-1 alone was 
able to induce ACT expression in cortical cultures. There is a small 
synergistic effect of adding dexamethasone together with IL-I. 
(B) Cultures similarly prepared from cerebellum and brain stem 
showed a similar response to IL-1 and examethasone, as did the 
cortical cultures. 
coid agonist dexamethasone to induce the expression of 
ACT in cultures of human fetal glial cells growing in defined 
medium. We also determined whether mixed glial cultures 
from different brain regions exhibit differential sensitivity 
to these factors. As shown in Figure 2A, addition of human 
recombinant IL-la (250 U/ml) induced an increase in the 
amount of ACT messenger RNA in subconfluent mixed 
glial cells from the frontal cortex. Most of this response 
could be elicited by IL-1 alone. There was a small syner- 
gistic effect of the further addition of dexamethasone (1 
#M) on the level of ACT mRNA. Cerebellum and brain 
stem cultures also exhibited an increase in the amount of 
ACT mRNA when treated with dexamethasone and IL-1 
(Figure 2B). The induction was similar to, or somewhat 
lower than, that seen in the cortical subconfluent cultures 
(Table 1). 
Previous in situ hybridization and GFAP immunocyto- 
chemistry on Alzheimer brain sections showed that large 
numbers of reactive astrocytes expressing ACT surround 
mature amyloid plaques (Abraham et al., 1988; Pas- 
ternack et al., 1989; Koo et al., 1991). The ACT and GFAP 
immunocytochemistry of mixed glial cultures grown to 
confluence in serum-containing medium also indicated 
that the astrocytes were the primary cells capable of ex- 
pressing ACT in vitro (Figure 1). To confirm further that 
astrocytes were indeed the cells in which IL-1 induced an 
increase in ACT mRNA levels in mixed glial cultures, we 
removed the major contaminating cell-type microglial 
cells. Three procedures were employed. First, we devel- 
oped a procedure of light trypsinization, followed by the 
discard of the nonadherent cells (including microglia) and 
the retention of the adherent astrocytes. Second, the 
method of Lee et al. (1992) consists of vigorously shaking 
mixed glial cultures and removing the microglial cells that 
are released into the culture medium. Finally, H-Leu-O- 
Methyl Ester hydrochloride is specifically toxic to microg- 
Table 1. Relative Increase in ACT mRNA Following Exposure 
of Human Mixed Glial Cultures to IL-1 and Dexamethasone 
Subconfluent Confluent 
Cortex 0.99 
6.17 1.06 
5.16 1.20 
5.20 1.2O 
Mean 5.51 1.11 
Cerebellum 3.35 1.71 
5.83 4.67 
3.47 3.87 
Mean 4.21 3.41 
Brain stem 2.05 
3.00 3.65 
4.70 5.06 
Mean 3.85 3.58 
Northern blot analysis and total cellular RNA from various brain regions 
was hybridized to an ACT probe, as described. Following autoradiogra- 
phy, the relative strengths of the bands in the samples from cells with 
and without addition of IL-1 and dexamethasone were determined by 
densitometer analysis. As discussed in the text, cortical cultures spon- 
taneously express ACT when they reach confluence and are then no 
longer responsive to the addition of exogenous IL-1. 
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Figure 3. Induction of ACT mRNA in Purified Astrocyte Cultures 
To confirm that the increase in ACT mRNA induced by IL-1 and dexa- 
methasone occurred in the astrocytes in the mixed glial cultures, we 
removed the microglial cells from subconfluent mixed cortical glial 
cultures and treated the remaining purified astrocyte cultures with 
IL-1 and dexamethasone. Three treatments were employed to remove 
microglial cells, as described in Experimental Procedures: by light 
trypsin digestion and the removal of the nonadherent cells, by vigorous 
shaking to remove nonadherent cells, and by trea:tment with 5 mM 
H-Leu-O-Methyl ester. The removal of the microglial cells by any of 
these three procedures had no effect on the induction of ACT mRNA 
by IL-1 and dexamethasone. 
lial cells (Giulian, 1987). Each of these three procedures 
was used to generate pure astrocyte cultures from the 
subconfluent pri mary mixed glial cultures. The relative ab- 
sence of the nonadherent microglial cells was confirmed 
by microscopic examination of cell morphology. All brain 
regions yielded similar proportions of purified astrocytes 
and microglia. The mixed culture and the different prepa- 
rations of purified astrocytes were immediately exposed 
to IL-1 and dexamethasone. The level of ACT mRNA was 
determined by Northern blot analysis and found to be in- 
creased to the same extent (Figure 3), indicating that the 
IL-l-sensitive cells are indeed the astrocytes. 
These results indicate that, like hepatocytes, astrocytes 
from the various areas of human fetal brain can respond 
to IL-1 and dexamethasone by increasing the expression 
of the acute phase protein ACT. Both areas prone to AIz- 
heimer's pathology, such as the cortex, and areas not so 
prone, such as the cerebellum, show similar responses 
to these inducing agents. 
Confluent Glial Cultures from Human Cortex, but 
Not Cerebellum or Brainstem, Spontaneously 
Express ACT as They Reach Confluence 
A lower baseline level of ACT messenger RNA was often 
seen in cultures derived from the cerebellum or brain stem 
as compared with the cortex. This observation indicated 
a potential difference in the ability of mixed glial cultures 
from different brain regions to initiate spontaneously an 
acute phase response and induced us to examine further 
the endogenous ACT expression under various condi- 
tions. Mixed glial cultures derived from human fetal cortex, 
cerebellum, and brain stem were allowed to grow to conflu- 
ence and then analyzed for the level of ACT mRNA. The 
results shown in Figure 4A and Table 1 indicate that conflu- 
ent cortical cultures express a high level of ACT messen- 
ger constitutively, and that no further induction results 
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Figure 4. Constitutive Expression f ACT in Cortical but Not Cerebel- 
lar or Brain Stem Mixed Glial Cultures and Blockage by Anti-lL-1 Re- 
ceptor Antibodies 
Cultures of mixed glial cells were prepared as described in Experimen- 
tal Procedures from human frontal cortex, cerebellum, and brain stem, 
grown in serum-containing medium to approximately 80% confluence. 
The cultures were then switched to N2 medium and allowed to reach 
confluence over the ensuing 12 hr. RNA was prepared and subjected 
to Northern blot analysis using an ACT probe. 
(A) Cultures prepared from the frontal cortex spontaneously expressed 
a high level of ACT mRNA, which could not be further induced by the 
addition of IL-1 and dexamethaeone. Incontrast, the cultures prepared 
from the brain stern or cerebellum at various times after they reached 
confluence continued to express the low level of ACT m R NA of subcon- 
fluent cultures and were still sensitive to induction by IL-1 and dexa- 
methasone. 
(B) Human cortical mixed glial cultures allowed to reach confluence 
either in the absence or presence of 2.5 I~g/ml blocking antibody to 
the I L-1 receptor.. Northern blot analysis of equal amounts of total RNA 
isolated from the two cultures indicated that the spontaneous level of 
ACT mRNA was greatly reduced in the presence of the antibody. 
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from the addition of dexamethasone and/or IL-1. In con- 
trast, confluent cultures of mixed glia derived from the 
cerebellum or the brain stem did not express ACT mRNA, 
despite the fact that they contained the same number of 
astrocytes as the cortical cultures. Furthermore, they con- 
tained the same number of microglia, as indicated by the 
fact that there was no significant difference in the number 
of microglia recovered from the various confluent cultures 
by vigorous overnight shaking (as assayed by staining with 
two macrophage/microglial cell-specific antibodies). The 
confluent cerebellar and confluent brain stem cultures 
can, however, be induced to express ACT by the addition 
of IL-1 and dexamethasone, just as can the subconfluent 
cultures from these brain regions shown in Figure 2. It 
therefore seemed likely that IL-1 is the inducing agent that 
is uniquely generated in the confluent cortical cultures and 
stimulates the endogenous astrocytes to express ACT. To 
test this hypothesis, a subconfluent mixed glial culture 
from human frontal cortex was supplemented with an anti- 
body that noncompetitively blocks IL-1 receptor function, 
and the cells were then allowed to grow to confluence. In 
comparison with an identical, untreated culture, there was 
a substantial reduction in the spontaneous expression of 
ACT mRNA in the presence of the blocking antibody (Fig- 
ure 4B). 
Because microglial cells are the primary source of IL-1 
in the brain and because purified astrocytes fail to express 
ACT when they reach confluence, it seems most likely 
that the differences in the cultures from different brain 
regions reflect differences in the microglial population. Be- 
cause no significant differences in the numberof microglial 
cells recovered from the confluent cortical and cerebellar 
cultures were observed the difference in astrocyte activa- 
tion likely resides in the ability of the microglial cells to 
synthesize and/or secrete IL-I. 
Microglial Cells Differ in Different Areas 
of Alzheimeds Disease Brain 
Because the in vitro experiments uggested that microglial 
cells derived from different parts of the brain might differ 
in their ability to synthesize or secrete IL-1, we analyzed 
sections of human Alzheimer and control brain for the 
presence of IL-l-expressing microglial cells. Griffin et al. 
(1989) had previously shown that Alzheimer brain cortex 
contains many-fold higher numbers of IL-l-positive gtial 
cells than normal cortex. As shown in Table 2, we have 
confirmed this result and have further found that IL-1- 
positive microglial cells are not increased to the same ex- 
tent in the cerebellum of Alzheimer brain. A similar conclu- 
sion has recently been reached by Cacabelos et al. (1994) 
and Sheng et al. (1994), who studied total IL-1 levels in 
various brain regions. 
In summary, the cerebellum not only fails to support 
mature amyloid deposition in Alzheimer's disease, but the 
in vitro studies also show that the cerebellar cultures are 
not prone to the production of IL-1 by microglial cells and 
the consequent expression of the amyloid-promoting fac- 
tor ACT. Thus, both in vitro and in vivo studies indicate 
that microglial production of IL-1 is aberrant in Alzheimer's 
disease, being increased only in those areas prone to amy- 
Table 2. Relative Number of IL-1-Expressing Microglial Cells in 
Different Brain Regions 
Subjects Cortex Cerebellum 
Aizheimer's 1 189 61 
disease 2 171 40 
3 140 40 
Mean 167 47 
Age-matched 4 22 9 
controls 5 13 10 
6 34 11 
Mean 23 10 
Microglial cells were identified inparaffin-fixed sections by immunohis- 
tochemistry for I L-1, as described, and the number of cells determined 
for fifty 40 x microscope fields (a total of 3.5 mm 2) in the sections from 
cortex or cerebellum of Alzheimer's or age-matched control individu- 
als, as indicated. 
Ioid pathology. The in vitro studies further suggest that 
the defect is intrinsic to the microglial cells, but it is also 
possible that an unidentified signaling molecule or lympho- 
kine is released only in cortical areas of the brain and 
primes the local microglial cells to produce IL-1 when they 
are cultured in vitro. 
IL-1 Fails to Induce ACT Expression 
in Rat Brain Astrocytes 
Although A~- and ACT-containing amyloid deposits are 
present in small numbers in the brains of most aged pri- 
mates, similar pathology has not been found in rodents 
(Wisniewski and Terry, 1973; Struble et al., 1985; Selkoe 
et al., 1987; Ab~'aham et al., 1989). Indeed, attempts to 
develop an animal model of Alzheimer's amyloid formation 
by generating transgenic mice that overexpress human 
13APP have been somewhat disappointing (e.g., Quon et 
al., 1991; Wirak et al., 1991). One possible explanation 
for these results is that the rodent brain may not be a 
fertile environment for A~ deposition, perhaps owing to 
a difference in the glial population. Certainly the relative 
number of glia compared with neurons is many-fold higher 
in humans. 
We have found that, in contrast o its clear role in initiat- 
ing the liver acute phase response and its ability to induce 
ACT expression in human astrocytes in culture (shown in 
Figure 2 and Figure 3), I1_-1 fails to increase ACT (contrap- 
sin) mRNA in astrocyte-rich mixed glial cultures from rat 
brain (Figure 5, compare lanes 1 and 2). Another lympho- 
kine, IL-6 (believed to be the immediate acute phase-in- 
ducing signal in v ivo [Baumann et al., 1989]) is also able 
to induce ACT expression in hepatocytes in the presence 
of dexamethasone. However, neither IL-6 alone nor IL-6 
in combination with IL-1 induces increased levels of ACT 
mRNA in rat brain gila. Several other proteins, such as 
transforming rowth factor 13 and epidermal growth factor, 
which have previously been shown to mediate the glial 
response to injury (Nieto-Sampedro, 1988; Birecree et al., 
1988), have also been tested and found incapable of induc- 
ing ACT expression in the cultured rat brain gila (data not 
shown). 
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Figure 5. Effect of Various Acute Phase Mediators on the Expression 
of Contrapsin/ACT in Rat Cultures 
Mixed glial cultures were grown to confluence in 10% serum- 
containing medium and then switched to N2 defined medium. The 
cells were then treated for 6 hr with no treatment (1), 250 U/ml IL-1 
(2), 1 ~M dexamethasone (3), 250 U/ml IL-1 + 1 p_M dexamethasone 
(4), 250 U/ml IL-6 (5), 250 U/ml IL-6 + 1 p.M dexamethasone (6), and 
250 U/ml IL-1 + 250 U/ml IL-6 (7). Total RNA was isolated from the 
cultures and subjected to Northern blot analysis using the contrapsin 
cDNA probe. The data show that he amount of ACT/contrapsin mRNA 
is greatly increased by treatment with dexamethasone alone, but not 
with IL-1 or IL-6. 
Dexamethasone Induces Expression of ACT 
in Cultured Rat Astrocytes 
Since dexamethasone is an important coregulator of ACT 
expression in rat hepatocytes during the peripheral acute 
phase response, but is without effect by itself, we tested 
the effect of this signal molecule on the rat brain mixed glial 
cultures. As shown in Figure 5 (lanes 1 and 3), treatment 
of quiescent cultures in serum-free medium with 1 ~M 
dexamethasone alone for 6 hr induced ACT mRNA 20- 
to 30-fold. Neither IL-1 nor IL-6 acted synergistically to 
increase the ACT induction by dexamethasone. 
In summary, rat and human glia exhibit very different 
abilities to express the amyloid-promoting factor ACT. Hu- 
man astrocytes are sensitive to IL-1, with a slight synergis- 
tic effect with dexamethasone, whereas the rat astrocytes 
are insensitive to IL-1 and instead show a striking response 
to dexamethasone. Even when allowed to reach conflu- 
ence, rat glial cultures still fail to express ACT, in contrast 
to the human cultures, which spontaneously express ACT 
if isolated from brain areas that are prone to developing 
Alzheimer's disease pathology. Together, these results 
suggest that the ability of a brain region--human or rat-- 
to express the acute phase protein ACT in vitro correlates 
with its ability in vivo to express mature Alzheimer amyloid 
pathology and reflects the presence of microglial cells 
able to synthesize and release the ACT-inducing lympho- 
cine IL-1. 
Discussion 
It is becoming increasingly clear that the human degenera- 
tive brain disorder called Alzheimer's disease results from 
a complex pathogenic pathway whose steps beyond the 
production of the AI5 protein are only beginning to be delin- 
eated. For instance, the association of the acute phase 
protein ACT with amyloid neuropathology first suggested 
the possibility that a brain acute phase response played a 
role in the conversion of amorphous AI3 deposits to mature 
amyloid (Abraham et al., 1988; Abraham and Potter, 1989; 
Rozemuller et al., 1990; Potter et al., 1991). The more 
recent findings that ACT binds tightly to AI3 peptide and 
is a strong amyloid-promoting factor, stimulating the poly- 
merization of AI3 into amyloid filaments in vitro, provide 
one mechanism by which ACT overexpression in certain 
regions of the Alzheimer brain could contribute to amyloid 
deposition in vivo (Potter et al., 1991; Potter, 1992; Ma et 
al., 1994). Other pathological chaperones may be similarly 
involved in amyloid production. Certainly, the fact that AI3 
is a normal constituent of body fluids and is released by 
all 13APP-expressing cells (Haass et al., 1992; Seubert et 
al., 1992; Shoji et al., 1992) indicates that the formation of 
mature amyloid deposits cannot depend on AI3 production 
alone. Instead, the turning point in the development of 
Alzheimer neu ropathology may be the disease- and tissue- 
specific production of pathological chaperones that direct 
when and where amyloid will form in the affected indi- 
vidual. 
The data of this paper support his model in several ways 
and suggest additional steps in the pathogenic pathway 
in Alzheimer's disease. First, they show that the expres- 
sion of the most Alzheimer-specific pathological chaper- 
one, ACT, is induced in human astrocytes by IL-1, a known 
acute phase-inducing agent that is overexpressed in AIz- 
heimer cortex. Moreover, different brain regions show dif- 
ferent capabilities for spontaneously expressing an acute 
phase reaction in vitro, with the same regional specificity 
with which the expression of acute phase proteins and 
the formation of filamentous amyloid occur in Alzheimer's 
disease. Finally, rat brain astrocytes differ from those of 
humans in failing to express acute phase proteins in re- 
sponse to IL-I. Thus, the normal inability of aged rodents to 
exhibit classic Alzheime~ike neuropathology may result 
both from differences in the AI3 sequence, with the rodent 
sequence being possibly less prone to polYmerization, and 
from the lack of appropriate pathological chaperones. Suf- 
ficient overexpression of a human APP gene carrying a 
familial Alzheimer's disease mutation may circumvent 
these deficits and lead to AI3 amyloid formation in trans- 
genic mice. 
What might initiate the inflammatory/acute phase cas- 
cade? The earliest pathological change that can be found 
in Alzheimer's disease brain--the accumulation of amor- 
IL-1 Induction of an AI3-Amyloid-Promoting Factor 
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phous deposits of AI3 protein-- is the most likely candidate. 
If such AI3 protein deposition occurs in an area such as 
the cerebellum, which does not appear capable of ex- 
pressing an inflammatory reaction or acute phase response, 
its pathological effect is evidently minor. The deposit re- 
mains amorphous, and there is no glial involvement and 
no resulting neuronal degeneration. However, in the gray 
matter of the cerebrum, especially in the hippocampus, 
amygdala, and neocortical regions, AJ3 production and 
amorphous aggregation may induce the observed microg- 
lial cell activation, division, and increased release of IL-1, 
which can then activate adjacent astrocytes. Indeed, AI3 
appears to have just such an activating effect on rat mi- 
croglia in vitro (Araujo and Cotman, 1992). The resulting 
astrocyte-led acute phase response would then produce 
the pathological chaperone ACT and other components 
of mature amyloid including, potentially, apoE. A number 
of proteases, such as clipsin (Nelson and Siman, 1990; 
Nelson et al., 1993) and some cathepsins (Cataldo and 
Nixon, 1990), are likely to be released during the inflamma- 
tion and subsequent acute phase response and may in- 
crease the cleavage of AI3 from its precursor. I~APP ex- 
pression itself is increased in reactive astrocytes induced 
by injury (Siman eta l . ,  1989; Otsuka et al., 1991) and 
in endothelial, neuronal, and glial cells exposed to IL-1 
(Goldgaber eta l . ,  1989; Forloni et al., 1992). Thus, an 
accelerating cycle of AI3 production and maturation into 
amyloid filaments can be established in areas of the brain 
in which glial cells can be recruited to participate in the 
pathology. Indeed, the two key cell types in this model, 
activated microglia and reactive astrocytes, are found 
within and surrounding the amyloid plaques in Alzheimer 
brain (Duffy etal . ,  1980; Itagaki etal. ,  1989; Pasternack 
etal., 1989; Abraham etal., 1990; Koo etal., 1991 ; McGeer 
etal. ,  1993). Ultimately, neuronal cell death occurs, per- 
haps as a direct consequence of toxicity of AI3 or AI3 fila- 
ments (Yankner et al., 1989, 1990). 
In summary, Alzheimer pathology and neuronal degen- 
eration may result from a complex pathogenic pathway in 
which initial widespread, amorphous AI3 protein deposition 
is followed in specific brain regions by a reaction of 
astrocytes and microglia to the deposits. Together, these 
lead to the production and release of ACT and other patho- 
logical chaperones and to the development of mature, fila- 
mentous amyloid. Thus, AIzheimer's disease may be an 
example of a disorder in which the organism's response 
to an initial insult makes an essential contribution to the 
final pathology. 
Experimental Procedures 
Preparation of Astrocyte Cultures 
Mixed glial cultures were prepared from portions of human brain and 
from whole brains of day 1 postnatal rats from which the meninges 
and mid and hind brain had been removed. Tissue samples from ana- 
tomically normal, intact human fetuses were retrieved after elective 
pregnancy termination with signed consent of the mother and in accor- 
dance with formal procedures and guidelines and of the Brigham and 
Women's Hospital Human Research Committee. All fetuses were ap- 
proximately 18-20 weeks gestational age, as determined by measure- 
ments of crown-rump length, foot length, and weight. The brains were 
removed within 2 hr of delivery and immediately, placed in Hank's 
balanced salt solution (HBSS) at 0°C. Rat brains or portions of human 
fetal brain were minced and suspended in HBSS supplemented with 
20 mM HEPES. The suspensions were allowed to settle and were 
washed 3 times in HBSS solution. They were then incubated at room 
temperature in 0.4 mg/ml trypsin (GIBCO) for 10 min. The supernatant 
was removed, and the sediment was resuspended in 2 ml of 0.25 mg/ 
ml DNase I and triturated 10 times gently with a Pasteur pipette. After 
2 rain, the supernatant was gently removed and placed in a separate 
tube. This was repeated 2 times, and the pooled supernatants were 
centrifuged at 1000 rpm for 10 rain. The pellet of cells was resuspended 
in 5 ml of medium (Dulbecco's minimal essential medium [DMEM], 
10% fetal calf serum [Hyclone defined], 1 mM pyruvate, 2 mM gluta- 
mine, Pen-Strep-Amphotericin [Sigma, Hybrimax]). The cells were 
plated on plastic dishes at 105 cells per milliter and grown until 50% 
confluent, with a medium change after 6 days. 
Pure astrocytes were prepared by three different protocols. In the 
first, plated cells were incubated with 0.2 mg/ml trypsin for 15 rain. 
The supernatant, including nonadherent cells, was discarded. The 
remaining cells were then washed with HBSS and placed in fresh 
medium. The second is a standard procedure for obtaining pure 
astrocyte cultures, carried out according to Lee etal. (1992). The sub- 
confluent mixed glial cultures were placed in a rotary shaker at 180 
rpm overnight. The supernatant and nonadherent cells were dis- 
carded, and the remaining cells were washed and supplemented with 
fresh medium. In the third protocol, cultures were treated with 5 mM 
H-Leu-O-Methyl ester for 18 hr according to Giulian (1987), after which 
the adherent cells were washed and fresh medium added. In all three 
procedures, the cells remaining were >95% astrocytes as determined 
by morphology and GFAP staining. The number of microglia removed 
from (and therefore present in) the mixed glial cultures was assessed 
by staining with two macrophage/microglial ce l-specific antisera, LN3 
and Mac1 (ICN), and were found to be equal from all brain re- 
gions _+10%-15° . 
One plate of mixed gila O r pure astrocytes was used in each experi- 
mental test. Complete medium was first replaced with serum-free N2 
medium (high glucose DMEM, 2 mM glutamate, 100 U/ml strep-amp, 
1 mM pyruvate, 5 ~g/ml insulin, 100 ~g/ml transferrin, 100 I~M putres- 
cine, 30 nM selenium, 20 nM progesterone) for 2 hr. The cells were 
then exposed to the different reatments for 6 hr, except where noted. 
Following treatment, he cells were harvested and their RNA isolated 
for Northern blot analysis. 
Northern Blot Analysis 
Total cellular RNA was isolated as described by Chirgwin etal. (1979). 
Briefly, cells ( -  10 mg of tissue) were washed with phosphate-buffered 
saline (PBS) and lysed directly on the culture plate in 1 ml of 4 M 
guanidinium isothiocyanate, 25 mM sodium citrate (pH 7), 0.5% sar- 
cosyl, 0.1 M 2-mercaptoethanol. The cell lysate was layered on 
top of 2 ml of 5.7 M cesium chloride and centrifuged overnight at 
39,000 x g. The RNA pellet obtained was resuspended in water, 
ethanol precipitated, resolubilized in water, and quantitated using 
spectrophotometry. Samples (3 #g) of RNA were denatured in 2.2 M 
formaldehyde, 50% formamide (v/v) and subjected to electrophoresis 
in a 1% agarose gel containing 2.2 M formaldehyde. The gels were 
stained with ethidium bromide and photographed to verify that each 
lane contained equal amounts of undegraded RNA. After transfer to 
nitrocellulose, the RNA was hybridized to 32P-labeled probe derived 
from either the hu man ACT cDNA or the rat ACT homolog, contrapsin, 
cDNA. Probes were labeled by priming with random hexamer oligonu- 
cleotides in the presence of [32P]dCTP (New England Nuclear). After 
hybridization, the membranes were washed under conditions of high 
stringency (0.1 x SSC, 55°C) and exposed to XAR-5 autoradiographic 
film (Kodak). Experiments were repeated at least 3 times with similar 
results. 
Immunocytochemistry 
Cells to be stained for GFAP or ACT were grown on poly-L-lysine- 
coated coverslips, fixed for 5 rain in 4% paraformaldehyde at room 
temperature, and then permeabilized with 0.1% Triton X-100 for 1 hr 
at room temperature. Coverslips with cells were then incubated with 
a 1:400 dilution of the primary antibody (mouse monoclonal anti-GFAP; 
Sigma) or rabbit polyclonal anti-ACT serum (Dako) at 4°C overnight. 
They were then washed 3 times for 5 min each with PBS. The cov- 
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erslips were then incubated with the secondary antibody (goat anti- 
mouse tet='amethylrhodamine B isothiocyanate conjugate [1:500 dilu- 
tion] or goat anti-rabbit fluorescein isothiocyanate conjugate [1:500 
dilution]; Sigma) for 1 hr at room temperature, washed 3 times, and 
mounted on slides for visualization and photography. 
Immunohistochemistry for IL-1 was performed as described by Grif- 
fin et al. (1989). Briefly, paraffin-fixed sections from Alzheimer and 
control brain were processed on slides through three changes of xy- 
lenes and rehydrated by processing slides through 100%, 95%, and 
75% ethanol. Sections were permeabilized in 0.05% Triton X-100 for 
10 min, followed by 0.2 N HCI for 20 min. Endogeneous peroxidase 
was blocked by placing sections in 0.6% H2OJmethanol for 30 min. 
Blocking of sections was performed in 20% goat serum for 30 rain. 
The appropriate dilution of the primary antibody (1:20 for anti-human 
IL-1 ~; Cistron) or direct application of monoclonal antibody LN3 (ICN) 
was then applied to the sections overnight at 4°C. For the IL-1 ,z stain- 
ing, a peroxidase-anti-peroxidase procedure was used. A 1:50 dilution 
of goat anti-rabbit IgG (Sigma) was applied to tissue sections for 30 
min. A 1:300 dilution of rabbit peroxidase anti-peroxidase was then 
applied to the section for 30 min. Finally, the sections were developed 
with diaminobenzidine, counterstained with hematoxylin, dehydrated, 
and mounted with coverslips. For LN3 staining, the Vector ABC Vecta- 
stain kit was used for peroxidase staining, after which sections were 
counterstained with hematoxylin, dehydrated, and mounted with cov- 
erslips. 
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